RPSM
KLRA

Royalty Pharma Sub-Manager’s Kailera Therapeutics KLRA Stock Holding History

Royalty Pharma Sub-Manager’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.1M Buy
+2,455,357
New +$54M 22.36% 3

Other funds holding KLRA

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Royalty Pharma Sub-Manager's KLRA Position: Q2 2026 in Review

Royalty Pharma Sub-Manager opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 2,455,357 shares worth $54.1M. The stake represents 22.36% of the portfolio and ranks #3 among its holdings.

85 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Royalty Pharma Sub-Manager held 2,455,357 shares of Kailera Therapeutics worth $54.1M as of Q2 2026.
  • Kailera Therapeutics was a new Royalty Pharma Sub-Manager position in Q2 2026.
  • Kailera Therapeutics made up 22.36% of Royalty Pharma Sub-Manager's portfolio in Q2 2026, its #3 holding.
  • 85 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Royalty Pharma Sub-Manager's 13F filing for Q2 2026, filed 14 Aug 2026.